Akeso, Inc. (HK:9926) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The study A Phase Ib/II Study of AK112 (PD-1 / VEGF bispecific antibody) in Combination With AK117 (anti-CD47 antibody) With or Without Chemotherapy in Advanced Malignant Tumors tests a new combo approach for hard-to-treat cancers. It aims to gauge safety and early signs of benefit, which can shape how Akeso, Inc. (HK:9926) positions its pipeline and future trials.
The trial evaluates AK112, an antibody that targets two cancer pathways, and AK117, an antibody that helps the immune system see tumor cells more clearly. Both are given by IV, alone or with standard chemotherapy, with the goal of improving treatment options for patients with advanced malignant tumors who have limited choices.
This is an interventional Phase Ib/II study, so it sits between early safety work and larger late-stage trials. It is non-randomized, uses parallel treatment groups, and is open label, meaning both doctors and patients know which drugs are given, with the main aim being treatment impact rather than pure observation.
Patient enrollment began after the first submission on 14 January 2022, marking the start of formal clinical testing for this combo. The study is now listed as completed, and the latest update was filed on 2 March 2026, which signals that follow-up and internal data review are likely well advanced even though formal results are not yet posted.
For investors, the key signal is that Akeso has now completed an early-to-mid stage trial on a complex immuno-oncology combo, which can support its valuation as a platform player in novel antibodies. This may improve sentiment toward HK:9926, especially if investors expect positive read-through to later trials, though the lack of posted results keeps outcome risk high.
In the broader market, this update keeps Akeso in the race with global oncology peers working on multi-target antibodies and immune-checkpoint combinations. Until detailed data emerge, share moves will likely reflect expectations rather than fundamentals, but completion de-risks execution and may help Akeso in future partnerships or fundraising rounds.
The study is completed and the record has been recently updated, with fuller details available on the ClinicalTrials.gov portal.
To learn more about HK:9926’s potential, visit the Akeso, Inc. drug pipeline page.